Skip to main content

SOP on Clinical Trial Monitoring Procedure

 Title: Clinical Trial Monitoring Procedure

Introduction and Purpose:

The purpose of this Standard Operating Procedure (SOP) is to outline the requirements for conducting interventional clinical trials at the clinical site It serves as a guide to promote quality and ensure adherence to Good Clinical Practice (GCP) standards. This SOP may also be applied to other types of clinical research studies to maintain high standards of quality.

Scope:

This SOP applies to all personnel involved in the monitoring of ESCTs, including clinical monitors, site coordinators, investigators, and other relevant staff.

Definitions and Acronyms:

  • Clinical Research: Encompasses all research involving human participants, excluding secondary studies using existing biological specimens or data collected without identifiers or publicly available data.
  • Clinical Trial: Refers to clinical research studies involving human participants assigned to an intervention designed to evaluate the effect(s) of the intervention on the participant and the effect being evaluated is a health-related biomedical or behavioral outcome.
  • CFR: Code of Federal Regulations
  • CRO: Contract Research Organization
  • EHR: Electronic Health Record
  • ERICA: Electronic Research Integrity and Compliance Administration
  • FDA: United States Food and Drug Administration
  • GCP: Good Clinical Practice
  • ICF: Informed Consent Form
  • ICH: International Council for Harmonization
  • IDS: Investigational Drug Services
  • IRB: Institutional Review Board
  • LAR: Legally Authorized Representative
  • PI: Principal Investigator
  • SOP: Standard Operating Procedure

Procedure:

Monitoring Expectations:

  • Monitoring will be performed as per the sponsor's requirements and should be scheduled based on the trial's complexity and risk.
  • Monitoring may involve on-site and/or central/remote monitoring to ensure the proper conduct and documentation of the trial.
  • The monitor's responsibilities include overseeing the trial, ensuring proper documentation, and facilitating communication between the sponsor and the investigator.

Scheduling On-Site Monitoring Visits:

  • Assigned monitors are expected to schedule monitoring visits with advance notice.
  • Monitors can visit for a mutually agreed-upon number of consecutive days per month for each protocol. The expected duration should be communicated to the study team.
  • Scheduling should consider space availability and potential exceptions for accommodating multiple studies in one visit.

Monitoring Visit Preparation:

  • The study team should identify mutually available dates, reserve necessary space, and schedule meetings with required parties.
  • Notification of the upcoming monitoring visit should be sent to potentially affected individuals.
  • The study team should prepare requested documentation, organize research charts, obtain and file any missing source documentation, and ensure data and case report forms (CRFs) are complete.
  • All essential documents should be filed, and training and delegation logs should be up-to-date.

On-Site Monitoring Visit Expectations:

  • Upon arrival, the monitor should notify the study team and sign in.
  • The study team should familiarize the monitor with their surroundings.
  • Monitors may share space with other site monitors.
  • Monitors should exhibit professional and ethical behavior.
  • Review of study materials should align with the initially requested items during the monitoring site visit setup.
  • Monitors won't have unrestricted access to the Electronic Health Record (EHR) but may have limited access as needed.
  • Monitors should not enter secured areas without authorized personnel.
  • All provided materials for review should be returned at the end of each business day.
  • Monitors are not allowed to duplicate research records.

Monitor Visit Follow-up:

  • The monitor should provide a summary of their review in a monitoring report and/or follow-up letter to the PI.
  • The PI and study team should address findings, data queries, and implement corrective actions.
  • The monitoring visit report should be maintained with other essential study documents.

Centralized/Remote Monitoring:

  • Centralized and remote monitoring can reduce on-site monitoring.
  • Limited remote monitoring may be possible from the clinical site EHR.
  • Regulatory records and IDS records may also be available for remote monitoring.
  • Requests for centralized/remote monitoring must be approved in advance.

Additional Considerations:

  • The monitor should schedule close-out monitoring visits as needed.
  • Any changes to sponsor-assigned monitoring personnel should be communicated to the study team.

Materials Required:

  • Current IRB approved protocol/amendment(s)
  • Current IRB Approved Consent Form(s)
  • Participant research charts
  • Access to electronic data capture (EDC) system
  • Access to essential documents / regulatory binders
  • Access to Vestigo

References:

  • 21 CFR Part 50 Subpart B: Protection of Human Subjects
  • 21 CFR Part 312 Subpart D – Investigational New Drug Application, Responsibilities of Sponsors and Investigators
  • ICH Guidance for Industry E6(R2): Good Clinical Practice

Document Approval:

Labels:

Popular posts from this blog

Human Genome Editing: FDA Draft Guidance Summary

Consideration for Developing Gene Editing Product  1. Genome Editing Methods: Genome editing can be achieved through nuclease-dependent or nuclease-independent methods. Nuclease-dependent methods involve introducing site-specific breaks in DNA using technologies like zinc finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), modified-homing endonucleases, and CRISPR-associated (Cas) nucleases. These breaks can lead to modification of the DNA sequence at the cleavage site. Nuclease-independent methods can change DNA sequences without cleaving the DNA and include techniques like base editing and synthetic triplex-forming peptide nucleic acids. The choice of GE technology should consider factors such as the mechanism of action, the ability to target specific DNA sequences, and the potential to optimize components for efficiency, specificity, or stability. 2. Type and Degree of Genomic Modification: Different GE approaches rely on DNA repair pathways such a...
Read more

Stem loop RT-PCR for Detection of siRNA in Animal Tissues

Step Loop RT-PCR for Detection of Small Interfering RNA (siRNA) The recent publications described a novel used the novel method for the detection of siRNAs using a TaqMan®-based approach. This approach utilizes similar strategy that has been used for microRNA detection. The approach is illustrated in below.  In brief, the RT step occurs in the presence of a stem-loop RT primer that is complementary to the last 6–10 bases of the 3′ end of the antisense strand of the target siRNA. The stem-loop primer contains an additional universal sequence at the 5′ end that facilitates a TaqMan-based detection strategy in the subsequent qPCR step. As in the case of microRNA, the forward primer for qPCR is sequence-specific for the target siRNA. For sequence compositions that yield a low predicted melting temperature (Tm), the forward primer is designed as a tailed primer to help increase Tm. Stem Loop PCR for SiRNA Detection Step 1: Preparation of liver and plasma samples for the quanti...
Read more

Human Gene Therapy for Neurodegenerative Diseases: FDA Guidance Summary

  Neurodegenerative diseases are a diverse group of disorders characterized by the progressive degeneration of the central or peripheral nervous system, and they can have various causes and clinical characteristics. This guidance document is a resource for sponsors on different aspects of product development, preclinical testing, and clinical trial design. It acknowledges the unique challenges and considerations associated with developing GT products for such complex and varied diseases. Below are the key summaries from the guidance. CONSIDERATIONS FOR CHEMISTRY, MANUFACTURING AND CONTROLS (CMC) The considerations for Chemistry, Manufacturing, and Controls (CMC) when developing gene therapy (GT) products for the treatment of neurodegenerative diseases are crucial for ensuring the safety and efficacy of these advanced therapies. Here, we will elaborate on the specific CMC considerations outlined in your text: Route of Administration and Product Volume: Neurodegenerative diseases oft...
Read more

FDA Guidance on Studying Multiple Versions of Cellular or Gene Therapy Products in Early-Phase Clinical Trials

 The purpose of this guidance is to offer advice to sponsors interested in conducting early-phase clinical trials for a single disease involving multiple variations of a cellular or gene therapy product. Sponsors aim to gather preliminary safety and efficacy data for these product variations within a single clinical trial. It's important to note that even though multiple product versions are studied together, each version is distinct and typically requires a separate investigational new drug application (IND) submission to the FDA. The primary goal of these early-phase clinical studies is to inform decisions about which product version(s) should be advanced for further development in later-phase trials. As such, these studies are not designed to provide the main evidence of effectiveness needed for a marketing application. They are generally not statistically powered to demonstrate a significant difference in efficacy between the different study arms. In this guidance, the FDA prov...
Read more

ICH Q8 (R2) Pharmaceutical development (CHMP/ICH/167068/04)

 ICH Q8 (R2) is a guideline titled "Pharmaceutical Development" (CHMP/ICH/167068/04). This guideline is part of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) and provides recommendations for the pharmaceutical development of medicinal products. It offers a structured approach to the development of pharmaceutical products to ensure their quality, safety, and efficacy. Here's an elaboration of ICH Q8 (R2): 1. Purpose of ICH Q8 (R2): The primary purpose of ICH Q8 (R2) is to provide a systematic and science-based approach to pharmaceutical development. The guideline aims to facilitate the design and development of high-quality pharmaceutical products that meet the needs of patients and regulatory authorities. 2. Scope: ICH Q8 (R2) applies to the development of all types of pharmaceutical products, including small molecules, biotechnological products, and other complex medicinal products. 3. Pharmaceutical Develop...
Read more